Telix and SHINE Partner for Lutetium-177 Supply
Telix announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for highly pure no-carrier-added (n.c.a.) lutetium-177 (177Lu)
Source: medindia.net
77lu News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from 77lu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In 77lu Today - Breaking & Trending Today
ITM Isotope Technologies Munich SE: ITM Announces First Patient Treated in Second Phase III Trial, COMPOSE, with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the first patient has been treated in its second pivotal phase III clinical trial, COMPOSE
Source: finanznachrichten.de
ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors at ASCO-GI
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the presentation of the study design for its phase III trial, COMPOSE (NCT04919226), at the
Source: finanznachrichten.de
Novartis Pharma AG: Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
Novartis Pharma AG: Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study 177 Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or death (median rPFS benefit of 5 months) compared to best standard of care alone 1 Significant improvement demonstrated in all key secondary endpoints, including time to first symptomatic skeletal event,...
Source: finanznachrichten.de